IP Library › Patent Application 16546018
Patent Application
App. No. 16/546,018

Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/546,018
Abstract

The present invention relates to differentiation of stem cells into a homogeneous endocrine progenitor cell population suitable for further differentiation into pancreatic beta-cells. The present invention provides methods for obtaining NGN3/NKX2.2 double positive endocrine progenitor cells by exposing precursor cells to a TGF-β type I receptor inhibitor, a BMP antagonist, an adenylate cyclase activator and nicotinamide and/or exposing to the precursor cells to a selection of small molecules.

Claims (19)

1 . A cell culture medium comprising:

a) a TGF-β type I receptor inhibitor,

b) a BMP antagonist, wherein the BMP antagonist is noggin, and

c) an adenylate cyclase activator.

2 . The cell culture medium according to claim 1 , wherein the TGF-β type I receptor inhibitor is SB431542.

3 . The cell culture medium according to claim 1 , wherein the adenylate cyclase activator is forskolin.

4 . The cell culture medium according to claim 1 , further comprising a small molecule selected from the group consisting of gefitinib, JNK inhibitor VIII.

5 . The cell culture medium according to claim 4 , wherein the cell culture medium comprises gefitinib and JNK inhibitor VIII.

6 . A method for obtaining NGN3/NKX2.2 double positive endocrine progenitor cells, comprising exposing pancreatic endoderm cells to a medium comprising

a) a TGF-β type I receptor inhibitor,

b) a BMP antagonist, wherein the BMP antagonist is noggin,

c) an adenylate cyclase activator, and

d) nicotinamide.

7 . The method according to claim 6 , wherein the TGF-β type I receptor inhibitor is SB431542.

8 . The method according to claim 6 , wherein the adenylate cyclase is forskolin.

9 . The method according to claim 6 , wherein the medium further comprises a small molecule selected from the group consisting of gefitinib, JNK inhibitor VIII.

10 . The method according to claim 9 , wherein the medium comprises gefitinib and JNK inhibitor VIII.

11 . The method according to claim 6 , wherein the TGF-β type I receptor inhibitor is SB431542, wherein the adenylate cyclase is forskolin, and wherein the medium further comprises a small molecule selected from the group consisting of gefitinib, JNK inhibitor VIII.

12 . The method according to claim 11 , wherein the medium comprises gefitinib and JNK inhibitor VIII.

Assignments (1)
MERGER Recorded Dec 8, 2023
From: TAKARA BIO EUROPE AB
To: TAKARA BIO EUROPE SAS
Reel/Frame 065806/0224 →